http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 09 Jul 2026 05:30:11 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Management+Changes/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html <p>Foresee Pharmaceuticals (TPEx: 6576) appointed Brian J. Groch as Chief Commercial Officer, effective July 1, 2026, according to a press release from the Taiwan-based biopharmaceutical company.</p> <p>Groch will oversee the commercial launch strategy for FP-001 42 mg, an investigational six-month subcutaneous long-acting injectable of leuprolide mesylate being developed for the treatment of central precocious puberty (CPP) in the United States, Taiwan, and potentially other markets.</p> <p>Groch has more than 30 years of experience in the pharmaceutical industry, including leadership roles at Remi Therapeutics, Shield Therapeutics, Veru Inc., and Horizon Therapeutics. He previously served as Director of Health Policy and Regional Sales at http://www.streetinsider.com/Corporate+News/Foresee+Pharmaceuticals+names+new+chief+commercial+officer/26749293.html Thu, 09 Jul 2026 05:30:11 -0400 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/Press+Releases/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690 http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6576" idsrc="xmltag.org" >Foresee Pharmaceuticals</span> (TPEx: 6576), ("Foresee") today announced the appointment of <person>Brian J. Groch</person> as Chief Commercial Officer, effective <chron>July 1, 2026</chron>. In this strategic executive role, Brian will oversee Foresee's global commercial launch strategy and preparations for FP-001 42 mg (six-month ready-to-use subcutaneous long-acting injectable of leuprolide mesylate) for the treatment of central precocious puberty (CPP) in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location>, and potentially other markets.</p> <p>Brian is a seasoned healthcare executive with more than 30 years of industry background and http://www.streetinsider.com/PRNewswire/Foresee+Pharmaceuticals+Appoints+Brian+J.+Groch+as+Chief+Commercial+Officer+to+Spearhead+Commercial+Launch+of+FP-001+42+mg+for+Central+Precocious+Puberty/26749292.html Thu, 09 Jul 2026 05:30:00 -0400 6576 6576 A.26756439 A.50216915 O.15644680 O.45210133 O.67420690